Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dolasetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 8/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 7/20 | 0.72 |
| ▸ | HTR3B | O95264 | 7/20 | 0.72 |
| ▸ | HTR3D | Q70Z44 | 7/20 | 0.72 |
| ▸ | HTR3C | Q8WXA8 | 7/20 | 0.72 |
| ▸ | HTR1A | P08908 | 2/20 | 0.72 |
| ▸ | HTR2B | P41595 | 2/20 | 0.72 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.72 |
| ▸ | HTR1D | P28221 | 1/20 | 0.72 |
| ▸ | HTR1B | P28222 | 1/20 | 0.72 |
| ▸ | HTR2A | P28223 | 1/20 | 0.72 |
| ▸ | HTR2C | P28335 | 1/20 | 0.72 |
| ▸ | HTR1E | P28566 | 1/20 | 0.72 |
| ▸ | HTR1F | P30939 | 1/20 | 0.72 |
| ▸ | HTR7 | P34969 | 1/20 | 0.72 |
| ▸ | HTR5A | P47898 | 1/20 | 0.72 |
| ▸ | HTR6 | P50406 | 1/20 | 0.72 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dolasetron SCHEMBL29356821 | 1.00 | HTR3A (1.00) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL14014817 | 1.00 | HTR3A (1.00) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL29390207 | 1.00 | HTR3A (1.00) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL13575734 | 1.00 | HTR3A (1.00) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL1819898 | 1.00 | HTR3A (1.00) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL24914047 | 1.00 | HTR3A (1.00) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL1819896 | 1.00 | HTR3A (1.00) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL14014809 | 1.00 | HTR3A (1.00) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL20769824 | 1.00 | HTR3A (1.00) | HTR3AKCNH2SLC6A4HTR3EHTR3B | |
| Dolasetron SCHEMBL4450258 | 1.00 | HTR3A (1.00) | HTR3AKCNH2SLC6A4HTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 21141 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144776-A1 | COMBINATION THERAPY FOR A DOPAMINE AGONIST | ALTO NEUROSCIENCE, INC. (US) | 2026-05-28 | — | — | US | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| US-20260130929-A1 | USE OF NK1 ANTAGONIST PRODRUG COMPOUND IN COMBINATION WITH 5-HT3 RECEPTOR ANTAGONIST | SHANGHAI SHENGDI PHARMACEUTICAL CO LTD (CN) | 2026-05-14 | — | — | US | claimed |
| US-12622895-B2 | Anti-neurodegenerative combinations and use for treatment of neurodegenerative diseases | ALTO NEUROSCIENCE, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| WO-2026090164-A1 | COMPOSITIONS COMPRISING ELISMETREP AND A SECOND THERAPEUTIC AGENT FOR TREATING OR PREVENTING MIGRAINE OR PAIN | KALLYOPE, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4725483-A1 | COMBINATION COMPRISING AT LEAST ONE 5-HT2A RECEPTOR ANTAGONIST AND AT LEAST ONE 5-HT3 RECEPTOR ANTAGONIST AND ITS MEDICAL USE | Université de Bordeaux (FR) | 2026-04-15 | — | — | EP | claimed |
| EP-4719552-A1 | INDUCTION OF GENERAL ANESTHESIA IN ADULTS UNDERGOING ELECTIVE SURGERY | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2026-04-08 | — | — | EP | claimed |
| US-6037360-A | Administration of 5-HT3 receptor antagonists to treat premature ejaculation | VIVUS, INCORPORATED (US) | 2000-03-14 | — | — | US | claimed |
| EP-0975327-A1 | USE OF 5HT3 ANTAGONISTS FOR PROMOTING INTESTINAL LAVAGE | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-02-02 | — | — | EP | claimed |
| WO-1999064046-A1 | MULTIVALENT AGONISTS, PARTIAL AGONISTS, INVERSE AGONISTS AND ANTAGONISTS OF THE 5-HT3 RECEPTORS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | claimed |
| US-5922341-A | Local administration of pharmacologically active agents to treat premature ejaculation | VIVUS, INCORPORATED (US) | 1999-07-13 | — | — | US | claimed |
| WO-1999017755-A2 | MEDICAMENTS | GLAXO GROUP LIMITED (GB) | 1999-04-15 | — | — | WO | claimed |
| CN-1201390-A | 5-HT3 receptor antagonists for treating dyskinesia | GLAXO WELLCOME INC (GB) | 1998-12-09 | — | — | CN | claimed |
| WO-1998047481-A1 | USE OF 5HT3 ANTAGONISTS FOR PROMOTING INTESTINAL LAVAGE | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-10-29 | — | — | WO | claimed |
| EP-0851756-A1 | 5-HT 3? RECEPTOR ANTAGONISTS FOR DYSKINESIA | GLAXO GROUP LIMITED (GB) | 1998-07-08 | — | — | EP | claimed |
| WO-1997047285-A1 | GASTRIC-RETENTIVE ORAL CONTROLLED DRUG DELIVERY SYSTEM WITH ENHANCED RETENTION PROPERTIES | DEPOMED, INC. (US) | 1997-12-18 | — | — | WO | claimed |
| WO-1997010823-A1 | 5-HT3 RECEPTOR ANTAGONISTS FOR DYSKINESIA | GLAXO GROUP LIMITED (GB) | 1997-03-27 | — | — | WO | claimed |